Food-sourced microbiome drugs get $101M megaround for Flagship's Kaleido
Mining food for safer sources of chemistry, microbiome startup Kaleido has closed a $101 million megaround to push its pipeline through the clinic.
The company, founded by Flagship back in 2015, is tackling rare genetic disorders, metabolic disease, oncology, and other disease targets. And it’s got four programs already in early-stage clinical trials. Kaleido says its trials are rapidly advancing thanks to two factors: its R&D engine lets the company study the human microbiome in a lab setting, and its compound library includes “sources of chemistry predominantly found in foods, significantly reducing safety concerns.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
